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Abstract
This paper describes a new method for enhancing the interaction of liposomes with cells. A novel class of cationic
poly(ethyleneglycol) (PEG)-lipid (CPL) conjugates have been characterized for their ability to insert into pre-formed vesicles
and enhance in vitro cellular binding and uptake of neutral and sterically-stabilized liposomes. The CPLs, which consist of a
distearoylphosphatidylethanolamine (DSPE) anchor, a fluorescent dansyl moiety, a heterobifunctional PEG polymer (Mr
3400), and a cationic headgroup composed of lysine derivatives, have been described previously [Bioconjug. Chem. 11 (2000)
433]. Five separate CPL, possessing 1^4 positive charges in the headgroup (referred to as CPL1^CPL4, respectively), were
incubated (as micellar solutions) in the presence of neutral or sterically-stabilized cationic large unilamellar vesicles (LUVs),
and were found to insert into the external leaflet of the LUVs in a manner dependent on temperature, time, CPL/lipid ratio,
and LUV composition. For CPL/lipid molar ratios 9 0.1, optimal insertion levels of approximately 70% of initial CPL were
obtained following 3 h at 60‡C. The insertion of CPL resulted in aggregation of the LUVs, as assessed by fluorescence
microscopy, which could be prevented by the presence of 40 mM Ca2. The effect of CPL-insertion on the binding of LUVs
to cells was examined by fluorescence microscopy and quantified by measuring the ratio of rhodamine fluorescence to protein
concentration. Neither control LUVs or LUVs containing CPL2 displayed significant uptake by BHK cells. However, a
3-fold increase in binding was observed for LUVs possessing CPL3, while for CPL4-LUVs values as high as 10-fold were
achieved. Interestingly, the increase in lipid uptake did not correlate with total surface charge, but rather with increased
positive charge density localized at the CPL distal headgroups. These results suggest that incorporation of CPLs into existing
liposomal drug delivery systems may lead to significant improvements in intracellular delivery of therapeutic agents. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
Liposomes have long been recognized for their po-
tential as in vivo drug carriers. For many conven-
tional drugs, such as anticancer agents and antibiot-
ics, a number of liposomal formulations have been
developed which exhibit pharmacological utility [1^
6]. Over the past decade, it has also become clear
that liposomal systems possessing cationic lipids are
0005-2736 / 01 / $ ^ see front matter ß 2001 Elsevier Science B.V. All rights reserved.
PII: S 0 0 0 5 - 2 7 3 6 ( 0 1 ) 0 0 3 2 7 - 3
* Corresponding author. Fax: +1-604-822-4843;
E-mail : fenske@interchange.ubc.ca
BBAMEM 78097 28-5-01 Cyaan Magenta Geel Zwart
Biochimica et Biophysica Acta 1512 (2001) 259^272
www.bba-direct.com
highly e¡ective transfection agents in vitro [7,8]. The
addition of cationic liposomes to plasmid DNA gives
rise to large complexes (commonly known as lipo-
plexes) that possess excellent transfection properties
in vitro, but which are ine¡ective in vivo due to their
rapid clearance from the circulation by the lung and
other ¢rst-pass organs. The need for a non-viral lip-
id-based system capable of systemic delivery of genes
to cells led to the recent development of stabilized
plasmid-lipid particles (SPLP) [9]. These particles are
small (V70 nm), contain a single copy of a plasmid
vector, possess long-circulation properties resulting
from a surface coating of poly(ethyleneglycol)
(PEG), and protect DNA from degradation by se-
rum nucleases. Current versions of SPLP exhibit
low transfection potency, however, due to low levels
of accumulation into target cells [10].
In order to optimize the intracellular delivery of
drugs (conventional or genetic) to cells, methods are
required for increasing the uptake of liposomes into
cells. Inclusion of speci¢c targeting information on
the liposome surface, such as antibody- [11^13], vi-
tamin- [14^18], oligopeptide- [19,20], or oligosaccha-
ride- [20] constructs speci¢c for a particular mem-
brane protein or receptor, have had limited success
in achieving this goal in vivo, despite promising in
vitro results. While speci¢c targeting of liposomes to
tissues is a desirable objective, non-speci¢c targeting
may also provide signi¢cant improvements in the ef-
fectiveness of liposomal carriers. For example, intra-
cellular delivery of relatively speci¢c and non-toxic
genetic drugs (antisense oligonucleotides and plas-
mids for gene therapy) could be expected to enhance
therapeutic e⁄cacy. In this paper, we describe a non-
speci¢c targeting approach that involves increasing
the electrostatic attraction between liposomes and
cells by incorporation of positively-charged lipid
molecules into preformed vesicles. The positively
charged lipid molecules are novel structures wherein
a cationic headgroup (containing between 1 and 4
positive charges) is separated from the phospholipid
anchor (and thus the vesicle surface) by a £exible,
hydrophilic polymer, in this case PEG. These cation-
ic PEG-lipid (or CPL) conjugates are labeled with a
dansyl group, which allows rapid and accurate quan-
ti¢cation using £uorescence techniques. The presence
of CPLs in LUVs results in dramatic increases in the
binding and uptake of vesicles by BHK cells in vitro.
We demonstrate the methodology for both cationic
and neutral vesicles, with an emphasis on the former,
as the cationic lipids present in lipoplex systems ap-
pear to play a direct role in stimulating uptake [21]
and endosomal release [22] in cells. Neutral systems
are also of interest as they comprise most conven-
tional delivery systems.
The approach described herein has been developed
and optimized within an in vitro context. Further
development of CPL-carriers, or application of the
post-insertion methodology to other targeted PEG-
lipids, may lead to in vivo applications ranging from
enhanced delivery of conventional drugs to gene
therapy.
2. Materials and methods
2.1. Materials
1,2-dioleoyl-phosphatidylcholine (DOPC), 1,2-dio-
leoyl-phosphatidylethanolamine (DOPE), and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(Liss-
amine Rhodamine B Sulfonyl) (rhodamine-PE) were
obtained from Avanti Polar Lipids. Cholesterol, Oc-
tyl-glucopyranoside (OGP), and HEPES were ob-
tained from Sigma Chemical Co. DODAC and
PEGCerC20, PEGCerC14, and PEGCerC8 were gen-
erous gifts from Inex Pharmaceuticals Corp. Slide-A-
Lyzer dialysis membrane cassettes were obtained
from Pierce.
2.2. Design and synthesis of cationic PEG lipids
The details of the design and synthesis of the CPLs
has been previously described [23]. The dansylated
cationic PEG-lipid conjugates (CPLs), illustrated in
Fig. 1, all have the same basic architecture, and con-
sist of four moieties, conjugated in the following
order: (i) a glycerolipid anchor (distearoylphosphati-
dylethanolamine (DSPE)), (ii) a lysine spacer con-
taining a dansyl-label on the O-amino group, (iii) a
PEG3400 chain, at the distal end of which is cova-
lently attached (iv) a positively charged headgroup
made of linked lysine residues. By modifying the
headgroup region, CPL were synthesized containing
one, two, three, and four positive charges, with two
varieties of the latter. As nearly all of the studies
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described in this paper involved the DSPE-CPL, the
nomenclature speci¢es the charge of the headgroup
as given in Fig. 1 (e.g., CPL4a).
2.3. Preparation of vesicles
Vesicles containing DOPE (or DOPC), the cationic
lipid DODAC and the stabilizing lipid PEGCerC20
were formed using a detergent dialysis method [9].
The lipids were co-dissolved in chloroform in the
appropriate ratios, following which the chloroform
was removed under a stream of nitrogen and placed
under high vacuum for 2 h. An aliquot of the non-
ionic detergent octylglucopyranoside (OGP) (1 M in
water) was then added to the dry lipid ¢lm, which
was incubated for 10^20 min at 60‡C with frequent
Fig. 1. Chemical structures of the DSPE-CPLs. Each CPL consists of a DSPE anchor, a dansylated lysine spacer, the PEG3400 spacer
chain, and a cationic headgroup (R) consisting of an amino group (CPL1), a lysine residue (CPL2), or linked lysine derivatives (CPL3,
CPL4a, CPL4b). The number of the CPL refers to the number of positive charges in the headgroup at physiological pH (where each
amino group will be protonated).
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vortexing. This was followed by addition of 20 mM
HEPES, 150 mM NaCl (pH 7.5), with further warm-
ing and vortexing until all the lipid was dispersed
and a clear solution was obtained. For 20 mg of
lipid, 0.125 ml of OGP and 1 ml of HBS were
used. The lipid-detergent solutions (1^2 ml) were
then transferred to Slide-A-Lyzer dialysis membranes
(3 ml volume) and exhaustively dialyzed at room
temperature against HBS over a period of 48 h. In
general, a total volume of 8^10 l of HBS was
used (4^5 changes of 2 l) for sample volumes of 1^
8 ml.
Vesicles of DOPC and DOPC/Chol (55:45) were
prepared by extrusion as previously described [24,25].
2.4. Insertion of CPL into preformed vesicles
The CPL were stored as micellar solutions in HBS
or methanol. The CPL and the vesicles were com-
bined to give the desired molar ratio (up to 11.6
mol% CPL relative to vesicle lipid), and incubated
for a given time at the desired temperature. For
most insertions, the standard conditions involved a
3 h incubation at 60‡C. Following insertion, the sam-
ples were quickly cooled on ice to room temperature,
and the CPL-LUV was separated from free CPL by
passage down a column (1.5U15 cm) of Sepharose
CL-4B equilibrated in HBS.
The insertion levels of CPL were measured by
£uorescence. In all cases, the vesicles contained either
0.25 mol% or 0.5 mol% rhodamine-PE, and the CPL
contained a dansyl group. After combining the CPL
and lipids, a 15-Wl aliquot (initial fraction) was set
aside for analysis. The amount of CPL inserted into
the vesicles could then be quanti¢ed by measuring
the initial dansyl/rhodamine (D/R) £uorescence ratio,
and the D/R ratio of the isolated CPL-LUVs. For
the rhodamine assay, the excitation wavelength was
560 nm, and the emission wavelength was 590 nm.
For the dansyl assay, the excitation wavelength was
340 nm, and the emission wavelength was 510 nm. In
general, the excitation and emission slit widths were
10 and 20 nm, respectively. The assay was performed
as follows: to an aliquot of the initial sample (2^3 Wl)
or the CPL-LUV (20^40 Wl) was added 30 Wl of 10%
Triton X-100 followed by 2 ml of HBS. The £uores-
cence levels of both the dansyl and rhodamine labels
were read consecutively using a wavelength program
as per the above parameters with an emission ¢lter of
430 nm. The %-insertion was calculated as fol-
lows:
%-insertion  D=RCPL-LUVU100=D=RINITIAL
2.5. Measurement of lipid concentrations
Lipid concentrations of LUVs were measured us-
ing the standard phosphate assay [26]. Following
CPL insertion, lipid concentrations were estimated
for cell binding studies from the rhodamine £uores-
cence.
2.6. Preparation of lipid samples for high-performance
liquid chromatography (HPLC) analysis
Prior to analysis by HPLC, lipids were extracted
from the aqueous phase using a Bligh^Dyer proce-
dure [27]. The organic phase was removed under a
stream of N2 gas, followed by 1 h under high vac-
uum. Samples were analyzed by HPLC at Northern
Lipids, Vancouver, BC, Canada.
2.7. Uptake of CPL-containing LUVs by
BHK cells
Approximately 105 BHK cells were incubated in
PBS/CMG medium with 20 nmol of DOPE/DO-
DAC/PEGCerC20 (84:6:10) LUVs containing either
(1) no CPL, (2) 5.6% CPL2, (3) 5.7% CPL3, or (4)
3.4% CPL4b. Incubations were performed for 1, 2, 4,
and 6 h at 4‡C and 37‡C, the former giving an esti-
mate of cell binding, and the latter of binding and
uptake. By taking the di¡erence of the two values, an
estimate of lipid uptake at 37‡C was obtained. For
each timepoint, the cells were washed twice with PBS
and then lysed with 600 Wl of phosphate bu¡er (pH
8.0) containing 0.1% Triton X-100 followed by lipid
and protein assays. Lipid concentrations were mea-
sured using rhodamine £uorescence, while protein
was determined using the BCA assay kit obtained
from Pierce. Where indicated, £uorescence micro-
graphs were taken on an Axiovert 100 Zeiss £uores-
cence microscope (Carl Zeiss Jena) using a rhod-
amine ¢lter from Omega Opticals (Brattleboro, VT)
with the following speci¢cations: Vex = 560 þ 20 nm,
LP = 600 nm, and DC = 590 nm.
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3. Results
3.1. Development of insertion protocol
The transfer of PEG-lipid monomers from micelles
to bilayers via the aqueous phase is a well-known
phenomenon [20,28^30]. For example, MPEG1900-
DSPE was found to insert into vesicles composed
of PC/cholesterol/PG to levels as high as 3 mol%
[30]. As the DSPE-CPLs are structurally similar
and form micellar solutions, we anticipated that in-
cubation of CPL solutions with vesicles would result
in incorporation of some CPL in the external vesicle
monolayer. The sections below describe the optimi-
zation of several variables that a¡ect the insertion
process.
3.1.1. CPL insertion
The insertion of CPL4b into neutral 100 nm
vesicles composed of DOPC is illustrated in Fig.
2A; experimental details are given in the ¢gure
legend. The co-elution of the dansyl and rhodamine
labels on a Sepharose CL-4B column demonstrates
incorporation of the CPL in the LUVs. In this case,
84% of the CPL was incorporated into the LUVs,
corresponding to a ¢nal insertion of 2.9 mol%, and
thus only a trace of free CPL is observed trailing the
CPL-LUV fractions. This is more clearly seen in Fig.
2B, where CPL4b has been inserted into more com-
plex positively charged vesicles composed of DOPE/
DODAC/PEGCerC20 (84:6:10). Here, the co-elution
of the two £uorescent labels at approx. 9 ml demon-
strates 70% insertion of the CPL into the vesicles,
corresponding to a ¢nal CPL concentration of 4.9
mol%. The free CPL micelles elute in a broad peak
centered at 16 ml, which is separate from the vesicle
peak, allowing for easy isolation of the CPL-LUV.
Once inserted, the CPL4b is retained and does not
exchange out of the vesicles. The CPL-LUV fraction
from Fig. 2B was re-eluted on the column of Sephar-
ose CL-4B. As shown in Fig. 2C, all of the CPL
remains with the LUVs.
3.1.2. E¡ect of time, temperature, and CPL/lipid ratio
on insertion
The e¡ects of incubation temperature and time on
the insertion process are shown in Fig. 3. CPL4a was
incubated in the presence of DOPE/DODAC/
Fig. 2. (A) Insertion of CPL4b into DOPC LUVs (100 nm).
DOPC LUVs (2.5 Wmol lipid) were incubated with 0.085 Wmol
CPL4b (total volume 240 Wl) at 60‡C for 3 h, following which
the sample was applied to a column of Sepharose CL-4B equili-
brated in HEPES-bu¡ered saline. One-ml fractions were col-
lected and assayed for dansyl-labeled CPL (8) and rhodamine-
PE (E) as described. (B) Insertion of CPL4b into LUVs (100
nm) composed of DOPE/DODAC/PEGCerC20 (84:6:10). LUVs
(5 Wmol lipid) were incubated with 0.355 Wmol CPL4b (total
volume 519 Wl) at 60‡C for 3 h, following which the sample
was applied to a Sepharose CL-4B column equilibrated in
HEPES-bu¡ered saline. One-ml fractions were collected and as-
sayed for dansyl-labeled CPL (8) and rhodamine-PE (E) as de-
scribed. The elution of free CPL (O) is also shown, demon-
strating a straightforward method for isolation of the CPL-
LUV. (C) Retention of CPL4b in LUVs (100 nm) composed of
DOPE/DODAC/PEGCerC20 (84:6:10). The main LUV fraction
from B was re-applied to a column of Sepharose CL-4B equili-
brated in HEPES-bu¡ered saline. One-ml fractions were col-
lected and assayed for dansyl-labeled CPL (8) and rhodamine-
PE (F) as described.
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PEGCerC20 (84:6:10) at room temperature (25‡C),
40‡C, and 60‡C, with aliquots withdrawn at 1, 3,
and 6 h. The highest insertion levels were achieved
at 60‡C, which was therefore used in subsequent in-
sertions. Although slightly higher insertion was ob-
tained at 6 h, we chose 3 h to minimize potential
sample degradation.
Aside from time and temperature, the parameter
that will have the greatest in£uence on ¢nal CPL
insertion levels is the initial CPL/lipid ratio. Assum-
ing about 70% insertion, a series of incubations
were performed with CPL/lipid ratios varying be-
tween 0.011 to 0.14, with the aim to achieve CPL-
LUVs containing 1, 2, 4, 6, 8, and 12 mol% CPL.
These results are shown in Fig. 4A, where it is seen
that the insertion level remains close to 70% up to
an initial CPL/lipid ratio of 0.095, above which it
drops to 50% for CPL/lipid = 0.14. Similar results
were obtained for other vesicle systems, including
DOPE/DODAC/PEGCerC14 and DOPE/DODAC/
PEGCerC8 (Fig. 4B). In general, the insertion levels
obtained with DODAC-containing samples fell in the
range of 65^82% for initial CPL/lipid6 0.1. The in-
sertion levels tend to be higher at lower CPL/lipid
ratios (Fig. 4B).
3.1.3. E¡ect of lipid composition on insertion
In order to see whether the insertion levels were
reduced in the absence of cationic lipid, several ex-
periments were performed on neutral vesicles con-
taining DOPC. The compositions examined were:
(A) DOPC, (B) DOPC/Chol, (C) DOPC/PEGCerC20,
and (D) DOPC/Chol/PEGCerC20. The results, shown
in Fig. 5, reveal signi¢cant levels of incorporation of
both CPLs, albeit lower for CPL4a (45^65%) than for
CPL4b (70^84%). The di¡erential behavior observed
for these two lipids is probably a re£ection of the
higher initial CPL/lipid ratio of the former. Never-
theless, comparison of the CPL4a neutral lipid results
with similar studies involving DOPE/DODAC/
PEGCerC20 reveal signi¢cantly reduced insertion in
the neutral LUVs. This may be due to reduced at-
traction between the negatively-charged DSPE an-
chor and the membrane surface. Regardless, the re-
sults demonstrate that signi¢cant insertion can be
achieved for both neutral and positive vesicles.
A large number of insertions have been performed
using other CPLs in addition to the CPL4b and
Fig. 3. E¡ect of time and temperature on the insertion of
CPL4a into DOPE/DODAC/PEGCerC20 LUVs. Insertions were
performed at 60‡C (R), 40‡C (F), and 25‡C (8). For each of
the three temperatures, 3 Wmol lipid was combined with
0.13 Wmol CPL (total volume 240 Wl). At 1, 3, and 6 h, 1 Wmol
of lipid was withdrawn and cooled on ice to halt insertion of
CPL. The samples were passed down a Sepharose CL-4B col-
umn to remove excess CPL, and assayed for CPL insertion.
 
 
 
    
Fig. 4. (A) E¡ect of initial CPL/lipid ratio on ¢nal CPL4b inser-
tion levels in LUVs composed of DOPE/DODAC/PEGCerC20
(84:6:10). Initial CPL/lipid ratios were 0.011, 0.024, 0.047,
0.071, 0.095, and 0.14. Final mol% inserted (8) : 0.8, 1.8, 3.4,
5.0, 6.5, and 7.0. The right-hand axis represents percent inser-
tion (F). See text for further details. (B) E¡ect of initial CPL/
lipid ratio on the %-CPL inserted into several representative
LUV formulations. (E) CPL4a inserted into DOPE/DODAC/
PEGCerC20 (84:6:10); (F) CPL4a inserted into DOPE/DO-
DAC/PEGCerC14 (84:6:10); (W) CPL4a inserted into DOPE/
DODAC/PEGCerC8 (79:6:15); (O) CPL4b inserted into
DOPE/DODAC/PEGCerC20 (84:6:10); (b) CPL3 inserted into
DOPE/DODAC/PEGCerC20 (84:6:10).
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CPL4a (for some representative results, see Fig. 4B).
Although there are some composition-dependent ef-
fects, in general we observe between 60^80% inser-
tion for initial CPL/lipid ratios6 0.1, with higher in-
sertion observed at lower CPL/lipid ratios. Some
minor trends are worth noting. The quantity of
PEG-Cer present in the LUV a¡ects the ¢nal inser-
tion levels. As the PEGCerC20 content was increased
from 4 to 10 mol%, the insertion level of CPL4b fell
from 71% to 62% (not shown).
3.1.4. E¡ect of CPL insertion on LUV lipid
composition
The insertion of up to 7 mol% CPL into the ex-
ternal lea£et of an LUV might be expected to have
some e¡ect on vesicle structure or composition. Of
special concern was the possibility that incorporation
of CPL might lead to expulsion of some PEGCerC20,
which exchanges out of eggPC vesicles with a half-
life for dissociation s 13 days [9]. This was examined
by measuring the lipid composition of DOPE/DO-
DAC/PEGCerC20 LUVs by HPLC before and after
the insertion of CPL4b. As shown in Table 1, the
insertion of 3.5 and 6 mol% CPL4b had no signi¢cant
e¡ect on lipid composition, other than a small de-
crease in PEGCerC20 content (from 8.3 to 7.5 mol%,
relative to total lipid). It should be noted that the
presence of 40 mM Ca2, which prevents or reverses
vesicle aggregation (see Section 3.1.5), had no e¡ect
on CPL insertion levels (Table 2) or vesicle compo-
sition (Table 1).
3.1.5. E¡ect of CPL insertion on vesicle aggregation
When examined under the £uorescence micro-
scope, DOPE/DODAC/PEGCerC20 LUVs labeled
with 0.5 mol% rhodamine-PE exhibit a di¡use red
background £uorescence. Following insertion of
CPL4b, large aggregates can be observed (data not
shown). This aggregation can be reversed by the ad-
dition of 40 mM Ca2, following which a di¡use red
Fig. 5. Insertion of CPL4a and CPL4b into neutral vesicles. The
initial CPL/lipid ratio was 0.065 for the CPL4a (open bars)
(2.5 Wmol lipid and 0.21 Wmol CPL) and 0.034 for the CPL4b
(shaded bars). Samples were incubated at 60‡C for 3 h. The
DOPC and DOPC/Chol LUVs were prepared by extrusion,
while the others were prepared by detergent dialysis. Sample
compositions: (A) DOPC, (B) DOPC/Chol (55:45), (C) DOPC/
PEGCerC20 (90:10), (D) DOPC/Chol/PEGCerC20 (45:45:10).
Table 1
E¡ect of insertion of CPL4b into DOPE/DODAC/PEGCerC20 (84:6:10) LUVs on vesicle composition
Mol% CPLa4b Lipid composition determined from HPLC (mol%)
DOPE DODAC PEGCerC20 DOPE/PEGCerCb20
0 83.5 þ 0.1 8.3 þ 0.2 8.3 þ 0.1 10.1 þ 0.1
3.5 84.1 þ 0.2 8.3 þ 0.01 7.5 þ 0.2 11.2 þ 0.2
5.7 84.3 þ 1.0 8.2 þ 0.1 7.5 þ 0.1 11.2 þ 0.3
5.9c 83.9 þ 0.6 8.4 þ 0.01 7.7 þ 0.2 10.9 þ 0.3
aMol% insertion determined from dansyl/rhodamine £uorescence ratio.
bMolar ratio.
cInsertion and isolation were performed in the presence of 40 mM Ca2.
Table 2
E¡ect of calcium on the insertion of CPL4b into DOPE/DO-
DAC/PEGCerC20 (83.5:6:10) LUVs
[Ca2]
(mM)
Initial
CPL/lipid
%
Insertion
Mol%
CPL inserted
0a 0.082 70 5.7
0a 0.082 75 6.1
40b 0.082 72 5.9
40c 0.082 71 5.8
40 0.049 74 3.6
aResults from two separate vesicle preparations.
bCalcium was present during insertion and removal of excess
CPL on Sepharose CL-4B.
cCalcium was added following CPL removal on Sepharose CL-
4B.
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£uorescence is again observed with no aggregates.
The presence of calcium prevents the formation of
aggregates. Interestingly, neither the CPL insertion
levels (Table 2), the composition of the CPL-LUVs
(Table 1), nor the diameters of the CPL-LUVs
(Table 3) are altered by the presence of calcium.
Quasi-elastic light scattering (QELS) was used to
examine the e¡ect of CPL insertion on particle diam-
eter (Table 3). In general, the insertion of CPL led to
a small increase in vesicle diameter, usually on the
order of 15 nm. Thus, the diameter þ S.D. of DOPE/
DODAC/PEG-Cer-C20 vesicles were found to in-
crease from 70 þ 22 nm to 87 þ 24 nm upon insertion
of 6 mol% CPL4b. Essentially identical results were
obtained in the presence of 40 mM Ca2. That the
aggregation observed by £uorescence microscopy
was not manifest suggests that the aggregates were
too large to be measured by QELS. The small ob-
served size increase may result from the presence of
the longer CPL PEG chains [30], which may be ex-
pected to increase the particle radius. The size in-
crease upon insertion of CPL is una¡ected by the
quantity of CPL inserted or by the quantity of
DODAC present in the vesicles. Identical size in-
creases were observed for CPL concentrations rang-
ing between 1.8 and 7.0 mol% (not shown). Further-
more, increasing the DODAC content from 6% to
18% had little e¡ect on CPL insertion or on the
size increase. In all cases, samples remained optically
clear, and there was no evidence of precipitation.
3.2. In vitro uptake of CPL-vesicles
As described in Section 2, estimates were obtained
for the uptake of various CPL-LUVs on BHK cells
incubated on PBS/CMG. The data, shown in Fig. 6,
reveals that the presence of positive charge on the
CPLs can lead to signi¢cant enhancement in uptake
by BHK cells. LUVs composed of DOPE/DODAC/
PEGCerC20 (and thus exhibiting a net positive
charge) showed little uptake on the BHK cells.
LUVs containing 5.6 mol% of CPL2 showed similar
low uptake values. Uptake was only slightly in-
creased by the presence of 5.7 mol% of CPL3. How-
ever, a signi¢cant increase in uptake (about 10-fold
at 6 h) was realized for CPL4b present at only
3.4 mol%. These results mirror our earlier studies
in which CPL4b-containing LUVs of DSPE/Chol/
Rho-PE exhibited 50-fold increased binding and up-
take on BHK cells [23].
The dramatic e¡ect of CPL insertion on LUV
binding to BHK cells is most clearly visualized using
£uorescence microscopy (Fig. 7). In the absence
of CPL, vesicles composed of DOPE/DODAC/
PEGCerC20 and containing a trace of rhodamine-
PE exhibit little binding to cells (Fig. 7A). Incorpo-
ration of 3 mol% CPL4b leads to high levels of vesicle
binding and uptake (Fig. 7B). Although much of the
lipid appears to be binding to the cell surface, some
small punctate structures can be seen, indicating that
Table 3
E¡ect of insertion of CPL4b into DOPE/DODAC/PEGCerC20
(84:6:10) LUVs on vesicle diameter
Lipid composition of
DOPE/DODAC/PEGCerC20
Mol%
CPL inserted
[Ca2]
(mM)
Diameter þ
S.D. (nm)
83.5:6:10 0 0 70 þ 22
0 40 72 þ 22
6.1 0 87 þ 24
5.8 40 88 þ 25
83.5:6:10 0 0 60 þ 17
5.5 0 75 þ 19
77.5:12:10 0 0 64 þ 18
6.3 0 82 þ 23
71.5:18:10 0 0 67 þ 21
6.2 0 80 þ 22
Fig. 6. Uptake of CPL-LUVs incubated in PBS/CMG on BHK
cells. Approximately 105 BHK cells were incubated with
20 nmol of DOPE/DODAC/PEGCerC20 (84:6:10) LUVs con-
taining (1) no CPL (8), (2) 5.6% CPL2 (E), (3) 5.7% CPL3
(R), and (4) 3.4% CPL4b (b). Incubations were performed at
4‡C and 37‡C, the former giving an estimate of cell binding,
and the latter of binding and uptake. By taking the di¡erence
of the two values, an estimate of lipid uptake at 37‡C was ob-
tained.
BBAMEM 78097 28-5-01 Cyaan Magenta Geel Zwart
D.B. Fenske et al. / Biochimica et Biophysica Acta 1512 (2001) 259^272266
Fig. 7. (A) Fluorescence micrograph of BHK cells following a 6-h incubation in the presence of DOPE/DODAC/PEGCerC20 vesicles
containing 0.5% rhodamine-PE. (B) As in A, except the vesicles contain 3 mol% of CPL4b. (C,D) Phase contrast micrographs of the
cells in A and B, respectively.
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uptake of vesicles is also occurring, as shown in Fig.
6. An important point to note is that the cells (Fig.
7C,D) appear healthy following incubation in the
presence of the CPL-LUVs.
Similar results to those described above have been
observed for BHK cells grown in the presence of 10%
FBS, for binding studies involving DOPE/DODAC/
PEGCerC20/Rho-PE LUVs containing both 3.2
mol% CPL4b and remote-loaded doxorubicin (drug-
to-lipid ratio = 0.12 mol:mol) (D.B. Fenske, A.L. Ng,
unpublished results). In addition, 10% FBS was also
present in our earlier studies that demonstrated en-
hanced binding of CPL4b/DSPE/Chol/Rho-PE LUVs
on BHK cells [23].
4. Discussion
One of the major remaining hurdles in liposomal
drug delivery is the problem of how to ensure that
the contents of a carrier system are taken up and
utilized by a speci¢c target cell. Cellular uptake of
liposomes involves adsorption or binding at the cell
surface, followed by endocytosis. Thus factors which
interfere with cellular binding will lead to low levels
of intracellular delivery. This is of particular impor-
tance for ‘stealth’ or long-circulating liposomes that
are coated with a surface layer of a hydrophilic poly-
mer such as PEG. The very characteristic of the PEG
coating which imparts long-circulation lifetimes ^ the
formation of a steric barrier that prevents interaction
with serum proteins will also minimize interactions
with cells. On the other hand, factors that enhance
surface binding may be expected to lead to increased
cellular uptake. One approach involves attaching
molecules speci¢c for membrane receptors to lipo-
somal surfaces. Possible candidates include oligopep-
tides [19,20], oligosaccharides [20], folate [14^16,18],
ribo£avin [17], or antibodies [11^13]. An alternate
approach is to modify the charge characteristics of
the liposome. It is well known that inclusion of either
negative [21,31^33] or positive [21] charges in lipo-
somes can lead to enhanced cellular uptake in vitro.
Cationic DNA^lipid complexes, which are positively
charged, e⁄cient in vitro transfection agents
[7,8,12,34,35], are taken up via endocytosis.
This paper describes a new approach for enhanc-
ing the interaction of liposomes with cells, a neces-
sary step in the eventual development of non-viral
systems capable of intracellular delivery. The ap-
proach involves the insertion of novel cationic
PEG-lipids into pre-formed liposomes, leading to a
cationic vesicle in which the positive charge involved
in cell interaction is located some distance away from
the vesicle surface. The process is illustrated in Fig. 8
for the insertion of a CPL4 into sterically-stabilized
LUVs composed of DOPE, the cationic lipid DO-
DAC, and PEGCerC20. This lipid composition was
chosen for study for two reasons: ¢rst, it allows for
e⁄cient entrapment of plasmid DNA within small
vesicular particles (SPLP) by virtue of the presence
of positively charged DODAC [9], and thus has po-
tential as a systemic gene delivery system (see below).
Secondly, this composition is representative of the
many sterically-stabilized drug delivery systems
which contain PEG-lipids. Unfortunately, both
SPLPs and the vesicles examined in the present study
exhibit low levels of uptake in vitro. Insertion of
CPLs leads to localization of positive charge above
the surface PEG layer, thereby allowing electrostatic
interactions between the CPLs and cell surfaces. For
in vitro studies, this should lead to increased cellular
interactions for both conventional- and PEG-con-
taining liposomes.
One might question the advantages of inserting
CPLs into pre-formed vesicles rather than simply in-
cluding the CPL as a lipid component during vesicle
formation. While the latter approach would work
with conventional vesicles, problems would arise in
formulation processes where plasmid DNA was
present, such as in the formation of SPLP. Encapsu-
lation of DNA within SPLP requires interactions be-
tween the cationic lipid DODAC and negatively
charged plasmid: if present, CPL would doubtless
interfere with this process, either by interacting
with plasmid (and thereby reducing the CPL quan-
tity present on the vesicle surface), or by altering the
optimal charge ratio for DNA encapsulation. The
post-insertion protocol has the advantage of being
completely general to any liposomal system.
The approach described in this paper for inserting
CPLs into pre-formed vesicles builds on several re-
cent related studies. The transfer of PEG-lipid con-
jugates from micellar phase to vesicles has been de-
scribed for MPEG1900-DSPE [30], PEG5000-DPPE
and PEG5000-DSPE [36], and for oligopeptide PEG-
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DSPE and oligosaccharide PEG-DSPE conjugates
[20]. In these studies, between 1 and 3 mol% of con-
jugate (relative to total lipid) was incorporated into
the target membranes. These values are signi¢cantly
lower than the maximum insertion levels we report
for the CPLs (up to 7 mol%). In addition, the oligo-
peptide/oligosaccharide PEG-DSPE conjugates could
be inserted to 1.2 mol% into vesicles containing
3 mol% MPEG-DSPE, demonstrating the potential
for using this approach with long-circulating lipo-
Fig. 8. Diagrammatic representation of the insertion of a CPL4 into sterically-stabilized LUVs composed of DOPE/DODAC/
PEGCerC20 (top). Incubation of the LUVs in the presence of CPL micelles results in the insertion of some CPL into the external leaf-
let of the LUV, giving rise to the structure shown at the bottom. Each black dot on the CPL represents a positive charge. The key
feature of the model lies in the ability to place external positive charge at some distance from the vesicle surface. The positive charges
on the DODAC (black shaded lipids) do not lead to enhanced interactions with cells due to shielding by the external PEG chains. By
varying the CPL and external PEG chain lengths, liposomal systems could be generated in which the CPL positive charge is shielded
during transport in the circulation, becoming exposed only as the PEGCer exchanges out of the vesicles. Such systems may have utili-
ty for in vivo applications (see text for more details). It should be noted that the PEG chains are drawn as extended or globular for
illustration purposes only, and are not intended to model actual chain conformations.
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somes. In our systems, high insertion levels (up to
7 mol%) could be achieved for vesicles containing
V7 mol% PEGCerC20. Although PEG-Cers will ex-
change from vesicles both in vitro [9] and during
circulation [37,38], only a small portion of the
PEGCerC20 appears to be lost during CPL insertion
(Table 1).
A recent study by Zalipsky and co-workers [14]
reported on the incorporation of folic acid PEG-
DSPE conjugates into vesicles, and demonstrated en-
hanced binding to cells expressing the folate receptor.
The best binding was observed for vesicles containing
only the folate PEG-DSPE conjugate. The presence
of additional mPEG-DSPE greatly reduced binding,
particularly when the length of the PEG in the two
molecules was identical. Enhanced binding was only
observed for vesicles containing folate-PEG3350-
DSPE and mPEG2000-DSPE. This mirrors our sys-
tem, where the Mrs of the PEG in the CPL and
PEG-Cers are 3400 and 2000, respectively, and sug-
gests we should be able to modulate cell binding by
varying the lengths of the two PEG spacers (see be-
low).
As shown in Fig. 6, cationic LUVs composed of
DOPE/DODAC/PEGCerC20 exhibit little uptake
when incubated on BHK cells. Although positively
charged vesicles exhibit enhanced binding to some
cell lines, this can be attenuated by the presence of
PEG on the liposome surface [21]. Clearly, for these
systems, the presence of 6 mol% of positively charged
DODAC leads to only low uptake levels after 6 h.
Incorporation of 5.6 mol% of CPL2 has little e¡ect
on uptake, which was only slightly improved in the
presence of 5.7 mol% CPL3. The best results were
obtained with the CPL4b (at 3.4 mol%), which pos-
sessed four positive charges. At 6 h incubation, a 10-
fold increase in uptake was observed relative to the
control vesicles. Several points can be surmised from
these data. The ¢rst is that the presence of positively
charged groups located some distance from the LUV
surface can lead to signi¢cant increases in cellular
uptake. In this case, the positive charges of the
CPL (PEG Mr = 3400) are located above the surface
coating of PEG (Mr = 2000), and thus are available
for interactions with cells. However, it is not total
charge alone that plays a role in enhanced cell bind-
ing. The quantity of positive charge present for the
CPL2 and CPL4b samples is approximately equal,
and yet the former shows little uptake compared to
the latter. The CPL3 sample has a greater total pos-
itive charge than the CPL4b sample, and yet exhibits
only a third of the uptake. It would appear that
localization of a su⁄cient positive charge density at
the distal end of the CPL molecule is an important
parameter in ensuring interaction with cells. At least
four charges seem to be required for e⁄cient cell
binding to occur.
The results of this paper demonstrate that the in-
teraction of LUVs with cells in vitro can be signi¢-
cantly enhanced by increasing the positive charge
present on the LUV surface by post-insertion of
CPL. The additional positive charge must be physi-
cally distant from the surface to be available for
interactions with cells, particularly when working
with polymer-coated vesicles that are designed for
minimal interactions with serum proteins and macro-
phages. This naturally leads to questions concerning
the design of next generation liposomal systems ca-
pable of systemic drug or gene delivery following i.v.
administration. First, it should be noted that the
CPL systems described here are unlikely to be of
direct utility as systemic delivery vectors. This is be-
cause the CPL employed contains a PEG3400 linker,
and thus the cationic groups at the end of the PEG
will extend beyond the PEG2000 ‘cloud’ provided by
the PEG-Cer components of the LUVs. Charged
liposomal systems are rapidly cleared from the circu-
lation following i.v. administration, and it would
therefore be expected that the systems employed
here would not exhibit the long circulation lifetimes
that lead to accumulation at disease sites such as
tumors. Strategies that could overcome this di⁄culty
include the possibility of inserting CPL containing a
shorter PEG linker, such as PEG1000. The positive
charge should then be shielded by the PEG2000 of
the PEG-Cer, leading to longer circulation lifetimes.
If necessary, a greater degree of shielding could be
achieved by insertion of the shorter-chain CPL into
systems containing PEG-Cer molecules prepared us-
ing PEG5000. A remaining problem concerns the need
to achieve exposure of the CPL after arrival at the
tumor site to stimulate uptake into cells. As we have
noted elsewhere [9,36,37], the PEG-Cer component
of liposomal systems can be designed to dissociate
over a time determined by the length of the acyl
chain contained in the ceramide anchor. If the
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PEG-Cer is designed to dissociate slowly, a situation
can be envisioned where LUV that have accumulated
at a disease site such as a tumor will lose the PEG
shield, thus exposing the CPL which stimulate up-
take. An alternative possibility is to post-insert lipids
containing speci¢c targeting ligands, that do not
stimulate clearance, at the end of the PEG linker.
Optimizing these systems for in vivo use will thus
involve varying the chain length of the PEG poly-
mers of both CPL and PEGCer, and of the fatty acyl
moieties which determine PEGCer exchange rates.
In summary, the results presented here demon-
strate the insertion of a new class of cationic ligands
into preformed liposomal systems, leading to in-
creased uptake into cells. The approach should be
generally applicable to liposomes containing small
molecule drugs (e.g., anticancer drugs) as well as
liposomes containing macromolecular drugs, such
as plasmids containing genes coding for therapeutic
proteins. Current studies are focused on applying this
approach to a new class of lipid-based DNA carrier
systems known as stabilized plasmid^lipid particles
(SPLPs) [9].
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